Associations between Malaria-Preventive Regimens and Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Ugandan Pregnant Women

Intermittent preventive treatment in pregnancy (IPTp) with monthly sulfadoxine-pyrimethamine (SP) is recommended for malaria-endemic parts of Africa, but efficacy is compromised by resistance, and, in recent trials, dihydroartemisinin-piperaquine (DP) has shown better antimalarial protective efficacy. We utilized blood samples from a recent trial to evaluate selection by IPTp with DP or SP of Plasmodium falciparum genetic polymorphisms that alter susceptibility to these drugs. The prevalence of known genetic polymorphisms associated with altered drug susceptibility was determined in parasitemic samples, including 375 collected before IPTp drugs were administered, 125 randomly selected from those receiving SP, and 80 from those receiving DP. ABSTRACT Intermittent preventive treatment in pregnancy (IPTp) with monthly sulfadoxine-pyrimethamine (SP) is recommended for malaria-endemic parts of Africa, but efficacy is compromised by resistance, and, in recent trials, dihydroartemisinin-piperaquine (DP) has shown better antimalarial protective efficacy. We utilized blood samples from a recent trial to evaluate selection by IPTp with DP or SP of Plasmodium falciparum genetic polymorphisms that alter susceptibility to these drugs. The prevalence of known genetic polymorphisms associated with altered drug susceptibility was determined in parasitemic samples, including 375 collected before IPTp drugs were administered, 125 randomly selected from those receiving SP, and 80 from those receiving DP. For women receiving DP, the prevalence of mixed/mutant sequences was greater in samples collected during IPTp than that in samples collected prior to the intervention for PfMDR1 N86Y (20.3% versus 3.9%; P < 0.001), PfMDR1 Y184F (73.0% versus 53.0%; P < 0.001), and PfCRT K76T (46.4% versus 24.0%; P < 0.001). Considering SP, prior to IPTp, the prevalence of all 5 common antifolate mutations was over 92%, and this prevalence increased following exposure to SP, although none of these changes were statistically significant. For two additional mutations associated with high-level SP resistance, the prevalence of PfDHFR 164L (13.7% versus 4.0%; P = 0.004), but not PfDHPS 581G (1.9% versus 3.0%; P = 0.74), was greater in samples collected during IPTp compared to those collected before the intervention. Use of IPTp in Uganda selected for parasites with mutations associated with decreased susceptibility to IPTp regimens. Thus, a potential drawback of IPTp is selection of parasites with decreased drug susceptibility.

[1]  Steve M. Taylor,et al.  Interactions between antenatal sulfadoxine-pyrimethamine, drug-resistant Plasmodium falciparum parasites and delivery outcomes in Malawi. , 2020, The Journal of infectious diseases.

[2]  P. Houzé,et al.  Effect of Drug Pressure on Promoting the Emergence of Antimalarial-Resistant Parasites among Pregnant Women in Ghana , 2020, Antimicrobial Agents and Chemotherapy.

[3]  P. Rosenthal,et al.  Antimalarial drug resistance in Africa: the calm before the storm? , 2019, The Lancet. Infectious diseases.

[4]  Richard J Maude,et al.  Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study , 2019, The Lancet. Infectious diseases.

[5]  D. Havlir,et al.  Monthly sulfadoxine–pyrimethamine versus dihydroartemisinin–piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial , 2019, The Lancet.

[6]  P. Rosenthal,et al.  Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda , 2018, Antimicrobial Agents and Chemotherapy.

[7]  P. Rosenthal,et al.  Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children , 2018, The Journal of infectious diseases.

[8]  D. Fidock,et al.  Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine , 2018, Nature Communications.

[9]  J. Bailey,et al.  Drug-Resistance and Population Structure of Plasmodium falciparum Across the Democratic Republic of Congo Using High-Throughput Molecular Inversion Probes , 2018, The Journal of infectious diseases.

[10]  P. Walker,et al.  Prevention of malaria in pregnancy. , 2018, The Lancet. Infectious diseases.

[11]  P. Rosenthal,et al.  Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance–Mediating Polymorphisms in Uganda , 2017, The Journal of infectious diseases.

[12]  D. Kwiatkowski,et al.  Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. , 2017, The Lancet. Infectious diseases.

[13]  D. Fidock,et al.  A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association study , 2017, The Lancet. Infectious diseases.

[14]  P. Rosenthal,et al.  Changing Antimalarial Drug Resistance Patterns Identified by Surveillance at Three Sites in Uganda , 2016, The Journal of infectious diseases.

[15]  S. Brooker,et al.  Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine in Ugandan Schoolchildren Selects for Plasmodium falciparum Transporter Polymorphisms That Modify Drug Sensitivity , 2016, Antimicrobial Agents and Chemotherapy.

[16]  M. Feeney,et al.  Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. , 2016, The New England journal of medicine.

[17]  M. Fay,et al.  Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. , 2016, The Lancet. Infectious diseases.

[18]  Steve M. Taylor,et al.  Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  S. Kariuki,et al.  Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin – piperaquine versus intermittent preventive treatment with sulfadoxine – pyrimethamine for the control of malaria during pregnancy in western Kenya : an open-label , three-group , randomised controlled , 2015 .

[20]  Steve M. Taylor,et al.  The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women. , 2015, The Journal of infectious diseases.

[21]  J. Gut,et al.  Impact of Antimalarial Treatment and Chemoprevention on the Drug Sensitivity of Malaria Parasites Isolated from Ugandan Children , 2015, Antimicrobial Agents and Chemotherapy.

[22]  L. Robinson,et al.  Ultra-Sensitive Detection of Plasmodium falciparum by Amplification of Multi-Copy Subtelomeric Targets , 2015, PLoS medicine.

[23]  P. Rosenthal,et al.  Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. , 2014, The Journal of infectious diseases.

[24]  P. Rosenthal,et al.  Protective Efficacy and Safety of Three Antimalarial Regimens for the Prevention of Malaria in Young Ugandan Children: A Randomized Controlled Trial , 2014, PLoS medicine.

[25]  P. Rosenthal,et al.  Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso , 2014, Antimicrobial Agents and Chemotherapy.

[26]  S. Brooker,et al.  Impact of Intermittent Preventive Treatment With Dihydroartemisinin-Piperaquine on Malaria in Ugandan Schoolchildren: A Randomized, Placebo-Controlled Trial , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  C. Plowe,et al.  Monitoring antifolate resistance in intermittent preventive therapy for malaria. , 2013, Trends in parasitology.

[28]  P. Rosenthal,et al.  Optimization of a Ligase Detection Reaction-Fluorescent Microsphere Assay for Characterization of Resistance-Mediating Polymorphisms in African Samples of Plasmodium falciparum , 2013, Journal of Clinical Microbiology.

[29]  P. Rosenthal,et al.  Selection of Known Plasmodium falciparum Resistance-Mediating Polymorphisms by Artemether-Lumefantrine and Amodiaquine- Sulfadoxine-Pyrimethamine but Not Dihydroartemisinin- Piperaquine in Burkina Faso , 2010, Antimicrobial Agents and Chemotherapy.

[30]  D. Chandramohan,et al.  High Resistance of Plasmodium falciparum to Sulphadoxine/Pyrimethamine in Northern Tanzania and the Emergence of dhps Resistance Mutation at Codon 581 , 2009, PloS one.

[31]  Jonathan Cox,et al.  Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. , 2008, The Journal of infectious diseases.

[32]  P. Rosenthal,et al.  Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. , 2006, The Journal of infectious diseases.

[33]  C. Plowe,et al.  Mechanisms of Resistance of Malaria Parasites to Antifolates , 2005, Pharmacological Reviews.